Q2 and H1 FY26 Results: Standalone Revenue Down 12%, Consolidated PAT Up 71%

Revenue declinedProfit growth above 25%EBITDA margin expansionResults restatedResults View source PDF Explain this filing

HESTERBIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.4%Reaction day

₹1635.00

prior close

₹1661.50

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.9%+2.4% vs market

Pharmaceuticals peers, median of 157sector+0.8%+2.6% vs sector

On the reaction day the stock moved 2.4 pts more than Nifty Microcap 250 and 2.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.2

10m

-0.0

15m

-0.4

30m

-1.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.4+0.9+2.4+0.8+2.6

Next day

+4.7+0.8+3.9+0.5+4.2

+3.1+0.7+2.3+0.4+2.7

+1.0+1.3-0.4+0.4+0.5

+2.8+0.5+2.2-0.1+2.9

+3.9+0.4+3.6-0.6+4.5

+1.7-1.5+3.1-1.2+2.8

15d

+0.3-2.4+2.8-1.8+2.1

-2.6-4.4+1.8-2.6-0.1

-5.8-7.2+1.4-5.4-0.5

-4.6-5.0+0.4-6.0+1.4

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Hester Biosciences Q2 FY26 standalone revenue fell 12% YoY to INR 645.79M, with PAT down 23% to INR 72.09M. H1 standalone revenue at INR 1,280.69M, PAT at INR 150.47M (down 15%). Poultry Healthcare grew 18% in Q2, while Animal Healthcare fell 50% on delayed government immunization programs. Consolidated PAT surged 71% in Q2 to INR 143.31M and 99% in H1 to INR 316.27M, aided by INR 88.90M forex gain on Tanzania borrowings. H9N2 vaccine received market authorization.

Likely market impact

Standalone weakness from delayed government orders; consolidated profits boosted by forex tailwinds. H9N2 vaccine approval brightens export outlook.